DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-445/S-012, S-015

Schering Corporation, Agent for
MSP Singapore Co., LLC
Attention: Beth DiDomenico, Ph.D, M.B.A.
Senior Manager, Global Regulatory Affairs
2000 Galloping Hill Road
Kenilworth, N.J. 07033

Dear Dr. DiDomenico:

Please refer to your supplemental new drug applications dated March 29, 2005, received March 30, 2005, and S-015, dated December 21, 2005, received December 22, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zetia (ezetimibe) Tablets.

We acknowledge receipt of your submissions dated July 19, 2005, and March 14 (email), 2006.

Supplement-012 provides for changes to the **CLINICAL PHARMACOLOGY**, *Special Populations*, *Race* subsection to state that "[s]tudies in Asian subjects indicated that the pharmacokinetics of ezetimibe were similar to those seen in Caucasian subjects." In **CLINICAL PHARMACOLOGY**, *Special Populations*, *Race*, and in the **CLINICAL STUDIES**, *Primary Hypercholesterolemia* subsections of the Zetia package insert, a statement regarding limited experience in non-Caucasians was deleted. This supplement was in response to a postmarketing study commitment as noted in our October 25, 2002 approval letter.

Supplement-015 provides for changes to the **ADVERSE REACTIONS** section, *Post-marketing Experience* subsection, to add the word "anaphylaxis" to the list of hypersensivity reactions.

We completed our review of these applications. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted draft labeling [package insert submitted March 14 (email), 2006](copy enclosed).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA.* Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-445/S-012, S-015**." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, M.S., R.Ph., Regulatory Project Manager, at (301) 796-1295.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Acting Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Eric Colman
3/16/2006 11:25:51 AM
Acting Deputy Division Director